

Is two-dimensional ultrasound necessary six weeks after insertion of the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) contraceptive?

Submission date 29/07/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 07/09/2021	Overall study status Completed	<input checked="" type="checkbox"/> Protocol
Last Edited 07/11/2023	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The correct position of the contraceptive levonorgestrel intrauterine system (LNG-IUS) can be confirmed by two-dimensional ultrasound (2DUS). However, best the timing of a routine 2DUS to confirm the correct position is subject to discussion. The main aim of this study was to assess how often the LNG-IUS is found to be incorrectly positioned on 2DUS during routine investigation at six weeks after insertion in the gynecological outpatient department. Additionally, the study will investigate the relation between malposition of the LNG-IUS and clinical symptoms like unacceptable bleeding patterns and pelvic pain.

Who can participate?

Women seeking a 52mg LNG-IUS (Mirena®), over 18 years of age, for contraception or treatment of heavy menstrual bleeding.

What does the study involve?

2DUS was performed to check the position of the IUD immediately after insertion and six weeks later. Women were excluded if they did not attend the appointment for 2DUS six weeks after insertion. Women were asked to complete questionnaires six weeks after insertion and were asked about bleeding pattern and pelvic pain.

What are the possible benefits and risks of participating?

No additional benefits or risks to participants are anticipated.

Where is the study run from?

Máxima Medical Centre (Netherlands)

When is the study starting and how long is it expected to run for?

May 2015 to December 2018

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Patty van der Heijden, pattyvanderheijden@gmail.com

Contact information

Type(s)
Scientific

Contact name
Miss Patty van der Heijden

ORCID ID
<http://orcid.org/0000-0002-5290-7646>

Contact details
Elkerliek Hospital
Wesselmanlaan 25
Helmond
Netherlands
5707HA
+31 615699305
pvanderheijden@elkerliek.nl

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
15.025

Study information

Scientific Title
Is two-dimensional ultrasound (2DUS) necessary six weeks after insertion of 52-mg LNG-IUS?

Study objectives
In this prospective cohort study we assessed the additional value of 2DUS six weeks after insertion. We described the frequency of malposition and the relationship between malposition of the LNG-IUS and clinical symptoms like bleeding pattern and/or pelvic pain.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/05/2015, Dagelijks Bestuur METC (Máxima Medisch Centrum, Locatie Veldhoven, Postbus 7777, 5500 MB Veldhoven; 3140-8888525; m.rutten@mmc.nl), ref: 15.025

Study design

Single-centre observational study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

See additional file

Health condition(s) or problem(s) studied

Diagnostics of malposition and complaints in women with 52-mg LNG-IUS

Interventions

Immediately after insertion of the LNG-IUS, the position of the LNG-IUS was assessed with the 2DUS by the resident, gynaecologist or physician assistant who performed the insertion. Six weeks after insertion a 2DUS was performed to evaluate the position of the LNG-IUS. Participants were asked to complete questionnaires 6 weeks after insertion. In the questionnaires women were asked about their bleeding pattern (presence of bleeding and/or spotting: 'no bleeding', 'regular menstruation', 'sometimes a day of spotting (maximum of once a week)', 'heavy menstrual bleeding', 'several days a week bleeding days', 'several days a week spotting days', 'continuously spotting', 'complete irregular cycle'). Women were asked to rate pelvic pain on a five-point Likert scale.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

levonorgestrel

Primary outcome measure

Incidence of malposition on 2DUS during routine investigation six weeks after insertion

Secondary outcome measures

Clinical symptoms at six weeks:

1. Unacceptable bleeding pattern measured using a questionnaire
2. Pelvic pain measured using a 5-point Likert scale

Overall study start date

23/05/2015

Completion date

31/12/2018

Eligibility

Key inclusion criteria

1. Women who visited our clinic for the insertion of a 52mg LNG-IUS (Mirena®) for contraception or treatment of heavy menstrual bleeding
2. Over 18 years of age

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

500

Total final enrolment

500

Key exclusion criteria

1. Presence of intracavitary polyps or fibroids on 2DUS prior to insertion
2. Unprotected intercourse one month prior to insertion if insertion took place outside menstruation
3. Women were excluded for analyses if no ultrasound was performed six weeks after insertion

Date of first enrolment

01/03/2015

Date of final enrolment

31/12/2016

Locations

Countries of recruitment

Netherlands

Study participating centre**Máxima Medical Centre**

de Run 4600

Veldhoven

Netherlands

5504DB

Sponsor information

Organisation

Máxima Medisch Centrum

Sponsor details

de Run 4600

Veldhoven

Netherlands

5504DB

+3140-8888525

m.rutten@mmc.nl

Sponsor type

Hospital/treatment centre

Website

<http://expats.mmc.nl/>

ROR

<https://ror.org/02x6rcb77>

Funder(s)

Funder type

Other

Funder Name

investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

01/10/2021

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. (pattyvanderheijden@gmail.com)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	In Dutch		10/08/2021	No	Yes
Protocol file	In Dutch		10/08/2021	No	No
Results article		04/10/2022	07/11/2023	Yes	No